RANK ligand and osteoprotegerin in myeloma bone disease

Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation

1998 • 5,369 citations

Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density

1997 • 5,058 citations

Bone Resorption by Osteoclasts

2000 • 3,797 citations

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function

1997 • 2,257 citations

Modulation of Osteoclast Differentiation and Function by the New Members of the Tumor Necrosis Factor Receptor and Ligand Families

1999 • 2,238 citations

Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

1999 • 1,832 citations

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

1999 • 1,621 citations

Minireview: The OPG/RANKL/RANK System

2001 • 1,385 citations

Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL

1998 • 1,177 citations

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

1996 • 1,091 citations

Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis1

1999 • 779 citations

TRANCE Is Necessary and Sufficient for Osteoblast-mediated Activation of Bone Resorption in Osteoclasts

1998 • 571 citations

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

2001 • 525 citations

Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation1

1999 • 524 citations

Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.

1989 • 501 citations

Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord

2000 • 496 citations

The Effect of a Single Dose of Osteoprotegerin in Postmenopausal Women

2001 • 487 citations

Osteoprotegerin inhibits prostate cancer–induced osteoclastogenesis and prevents prostate tumor growth in the bone

2001 • 453 citations

Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment

2001 • 419 citations

Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma

2000 • 397 citations

Multiple Myeloma

1997 • 389 citations

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma

2001 • 385 citations

Macrophage inflammatory protein-1α is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor κB ligand

2001 • 330 citations

Molecular mechanisms of osteolytic bone metastases

2000 • 325 citations

Bisphosphonates Pamidronate and Zoledronic Acid Stimulate Osteoprotegerin Production by Primary Human Osteoblasts

2002 • 310 citations

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity

2002 • 309 citations

Biology of Osteoclast Activation in Cancer

2001 • 303 citations

The Expression of Osteoprotegerin and RANK Ligand and the Support of Osteoclast Formation by Stromal-Osteoblast Lineage Cells Is Developmentally Regulated**This work was supported by Grant AG-04875 from the National Institute on Aging.

2000 • 292 citations

Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.

2001 • 291 citations

Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma

2002 • 289 citations

Human myeloma cells stimulate the receptor activator of nuclear factor-κB ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease

2002 • 268 citations

Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells

2002 • 248 citations

Osteoprotegerin and rank ligand expression in prostate cancer

2001 • 234 citations

Elevated Serum Concentrations of Hepatocyte Growth Factor in Patients With Multiple Myeloma

1998 • 214 citations

Effects of Immunosuppressants on Receptor Activator of NF-κB Ligand and Osteoprotegerin Production by Human Osteoblastic and Coronary Artery Smooth Muscle Cells

2001 • 211 citations

Osteoprotegerin diminishes advanced bone cancer pain.

2001 • 192 citations

Production of interleukin-1 by bone marrow myeloma cells

1989 • 191 citations

Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease

2001 • 172 citations

Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor κB ligand on adult T-cell leukemia cells

2002 • 167 citations

Myeloma bone disease

2001 • 167 citations

Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.

2003 • 156 citations

Bone metastatic LNCaP‐derivative C4‐2B prostate cancer cell line mineralizes in vitro

2001 • 154 citations

Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy.

2000 • 146 citations

Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma

1989 • 141 citations

Serum osteoprotegerin levels in healthy controls and cancer patients.

2002 • 133 citations

Functional expression of receptor activator of nuclear factor κB in Hodgkin disease cell lines

2001 • 133 citations

RANK (receptor activator of nuclear factor‐κB) and RANKL expression in multiple myeloma

2002 • 128 citations

Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy.

2001 • 117 citations

Serum osteoprotegerin levels are increased in patients with advanced prostate cancer.

2001 • 115 citations

Interactions between Cancer and Bone Marrow Cells Induce Osteoclast Differentiation Factor Expression and Osteoclast-like Cell Formation in Vitro

2000 • 96 citations

Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.

2001 • 96 citations

Cancer Cells Responsible for Humoral Hypercalcemia Express mRNA Encoding a Secreted Form of ODF/TRANCE That Induces Osteoclast Formation

2000 • 95 citations

Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy

1998 • 87 citations

Osteoprotegerin in Serum as a Novel Marker of Bone Metastatic Spread in Prostate Cancer

2001 • 49 citations

Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma

2002 • 24 citations